2025年9月,Mounjaro成为印度第二畅销药品,其驱动力是重量损失的功效和新的运载工具。 Mounjaro became India’s second-best-selling drug in September 2025, driven by weight-loss efficacy and new delivery devices.

Eli Lilly的Mounjaro在2025年9月的印度月度药品销售中名列第二, Eli Lilly’s Mounjaro surged to second place in India’s monthly pharmaceutical sales in September 2025, generating ₹80 crore—just behind Augmentin—after launching in March. 累计销售额达到了233亿卢比,其减肥效率为20-22%; 作为第一者, 产品在8月推出预装KwikPen设备. Cumulative sales reached ₹233 crore, fueled by its 20-22% weight-loss efficacy, first-mover advantage, and the August launch of pre-filled KwikPen devices. 销售量比新诺迪斯(Novo Nordisk)的韦哥维(Wegovy)增加43%, Sales rose 43% from August, outpacing Novo Nordisk’s Wegovy, which plateaued at ₹9 crore. 印度抗肥胖药品市场价值750亿卢比, 肥胖和糖尿病病例数量不断上升, 尽管产量较低, 但Mounjaro的单价较高, 产品表现强. India’s anti-obesity market, valued at ₹752 crore, is growing amid rising obesity and diabetes rates, with Mounjaro’s high unit price driving strong performance despite lower volume.